GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Institutional Ownership

Sutro Biopharma (FRA:S09) Institutional Ownership : 21.87% (As of Jun. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sutro Biopharma's institutional ownership is 21.87%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sutro Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sutro Biopharma's Float Percentage Of Total Shares Outstanding is 99.16%.


Sutro Biopharma Institutional Ownership Historical Data

The historical data trend for Sutro Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Institutional Ownership Chart

Sutro Biopharma Historical Data

The historical data trend for Sutro Biopharma can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 41.46 41.13 38.03 37.25 36.24 32.09 31.99 29.55 21.84 21.87

Sutro Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Sutro Biopharma (FRA:S09) Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma (FRA:S09) Headlines

No Headlines